

# Index

---

- Abbott Laboratories 38, 45–7  
abuse of process 231  
academic networks: Thailand 35–6,  
42–3  
Act Up–Paris 46–7, 52  
Adamson, R.L. 82  
African Regional Intellectual Property  
Organization (ARIPO) 218  
Agreement on Trade-Related Aspects  
of Intellectual Property *see* TRIPS  
Agreement  
agro-biotech industries 16  
seeds *see* seeds, illicit  
AIDS *see* HIV/AIDS  
American Chambers of Commerce  
(AmChams) 16–17, 33, 46  
Andersen, B. 80  
animal varieties 211, 228  
Anuradha, R.V. 84  
Argentina 58, 61  
patents 13–15, 25–6  
strengthening interests 16–19  
weakening interests 19, 20–25  
arogyapacha plant 80–81, 89, 92–3,  
102  
benefit sharers, definition of 91  
benefit sharing agreement, impact  
of 93–6  
identifying the Kanis 96–100  
conclusion 101–2  
key questions 85–6  
lessons learnt 100  
Arrow, K.J. 3  
Artelsmair, G. 131, 132  
Arthur, W.B. 213  
Arya Vaidya Pharmacy (AVP) 92, 93,  
95, 96  
*Astron Clinica Ltd and Others* (2008)  
219  
Atkinson, S. 219  
attorneys *see* lawyers  
Australia: patent ownership 183, 190,  
191, 192, 204  
corporate patenting 192–201  
ownership of US patents 189–90  
winners, patent system 188  
Austria 147, 189–90  
Bakels, R.B. 186  
Bale, Harvey 29  
Barton, J.H. 186  
Bates, M. 191  
Bayer 69  
BBC 63, 74  
Beigbeder, Y. 1  
Beland, D. 225  
Belgium 147, 151, 189–90  
Benford, R.D. 109  
Bessen, J.E. 1, 3, 183, 184, 185, 186,  
188, 204, 205, 227  
Bettig, R.V. 90, 176  
Bhatiasevi, A. 42  
Biehl, J. 20  
Bijoy, C.R. 86  
bilateral trade agreements (BTAs) 17,  
30  
biodiversity 35  
Convention on Biological Diversity  
(CBD) 86, 87–8, 94  
Biopatent Directive 129–30, 131–3,  
218  
conclusion 151–5  
'economy' frame: introduction of  
directive 133–4  
'ethics' frame: contestation of  
directive 134–6  
European Parliament, role of 137–9  
evaluation of 1998 outcome 142–5  
frame analysis 130–31  
frame constellation (1988–95) 136–7  
frame constellation (1995–98)  
139–42

- national implementation
  - (1998–2006) 147–8
  - frame constellation (1998–2003) 148–9
  - frame constellation (2004) 149–50
  - legislative outcomes 150–51
  - stem cells, human embryonic 145–7
- biopiracy 82, 91–2
  - see also* traditional knowledge
- biosafety: transgenic seeds 56, 58, 59, 61–2, 68–9, 70, 73–5
- Black, J. 137
- Blakeney, M. 84
- Bodoni, S. 231
- Boldrin, M. 183, 185
- Bolkestein, Frits 116, 117–18
- Borrás, S. 132
- Boseley, S. 42
- Bouwen, P. 108
- Boyce, Ralph 33–4
- Boyd, S.L. 82
- Boyle, J. 3, 154
- Brazil 35, 48, 58, 59, 61
  - compulsory licences 21, 50
  - patents 13–15, 25–6
    - strengthening interests 16–19
    - weakening interests 19–25
- breast cancer genes, patents on 140
- Bretthauer, L. 160, 166
- Brimelow, Alison 151
- Bristol-Myers Squibb (BMS) 41–2, 52, 201
- British Telecom 116
- Brush, S.B. 89
- Bt cotton *see under* India
- Buena Vista 163
- Burk, D.L. 153
- Bush, George W. 32
- business methods patents 205, 207, 222
- Butler, J.P. 49
- Byerlee, D. 82
  
- Calestous, J. 81
- Canada
  - patents 67, 189, 190, 195, 220
  - transgenic crops 57, 61
- cancer drugs 34, 46, 48, 52
- cancer genes, patents on 140
- Caribbean 18
- Cartagena Protocol 59
  
- Chaiya Sasomsab 48
- chemical sector/companies 16, 184, 188, 194, 195, 200, 201
- Chennells, R. 80, 86
- China 58, 59, 61
- CH (Computer Implemented Inventions) *see* Software Patents Directive
- Clinton, Bill 42, 47–8, 51
- cloning 144
- Coflexip v Stolt Comex* (2004) 230–31
- Cohen, J.I. 59, 61
- Cohen, W.M. 184, 185–6
- Cole, J.H. 185
- compulsory licences 21
  - Thailand 29–31, 37, 48–9
    - Oct 2001: universal health cover 37–8
    - Jan 2006: mobilization 39–41
    - historical decision 41–3
    - Sept 2006: military coup 44
    - chain reaction 44–7
    - May 2007: diplomatic mission 47–8
    - players 32–7
    - use of 30, 50
- computers/software sector 194, 200
  - see also* software *under* patents
- constitutional rights
  - medicines, access to 20, 21, 22, 25
- Convention on Biological Diversity (CBD) 86, 87–8, 94
- Cook, T. 80
- copyright: digital movie industry *see under* Germany
- Cornelli, F. 226
- Cornish, W. 231
- Correa, C.M. 1, 2, 29
- cost–benefit analysis 221
- cotton, Bt *see under* India
- counterfeiting 110
  - seeds 56, 57, 58, 59, 62, 65, 66, 74
- Cronin, D. 35
- Cystic Fibrosis Association, Danish 141
  
- David, P.A. 3, 84, 212
- Davies, L. 222
- Delta and Pine Land 60
- Denmark 147

- Denzau, A. 214  
*Deuel, In re* (1995) 232  
 developed countries 49, 87, 222  
   asymmetrical power relationships  
     30, 48  
   IP, innovation and costs 24  
   *see also individual countries*  
 developing countries 87, 90  
   asymmetrical power relationships 30  
   foreign knowledge and technology  
     14  
   ‘grow into’ IP regimes 23–5  
   pharmaceutical patents 31  
     Doha Declaration 30  
     TRIPS Agreement 19–20  
   research, transgenic crop 59  
   TRIPS agreement 19–20, 107–8  
   *see also individual countries*  
*Diagnostic Methods* (2006) 225–6  
*Diamond v Chakrabarty* (1980, US)  
   67, 132  
 DNA sequences and patents 135–6,  
   140, 142, 143–4, 146, 147–51, 152  
   incremental change 228  
   non-obviousness doctrine 232  
 Doberstyn, E.B. 42  
 Doern, G.B. 217  
 Doha Declaration 29–30, 34, 46, 47, 48  
 Drahos, P. 1, 2, 5, 16, 40, 107, 182,  
   200, 205, 218, 229  
 Dryzek, J. 130, 138  
 Du Pont 200  
 Ducor, P. 232  
 Dutfield, G. 80, 89, 135  
  
 Ebay 168  
 economics/economists 153, 154, 184,  
   215, 227, 229–30  
 Edwards, C.D. 187  
 EICTA (European Information &  
   Communications Technology  
   Industry Association) 114, 116,  
   121, 126  
*EISA/Second Medical Use* (1985)  
   223–4  
 Eisenberg, R. 223, 228  
 electronics/electrics industries 194, 195,  
   200  
 embryos  
   Biopatent Directive 143, 144, 145  
   human embryonic stem cells  
     145–7  
 Emmott, S. 131, 138  
 Enforcement Directive, IP 109–11  
   conclusion 123–4, 125–6  
   methodology: political claims  
     analysis 111–12  
   results 112–13  
     actors and actions 114–16, 118  
     framing 118–20  
 Ericsson 195  
 ETNO (European  
   Telecommunications Network  
   Operators Association) 116–17,  
   118, 120  
 Etro, F. 80  
 Europe 16  
   patents 67, 195, 211, 216, 222  
   EPC *see* European Patent  
     Convention  
   EPO *see* European Patent Office  
 European AIDS Treatment Group  
   (EATG) 47  
 European Alliance of Genetic Support  
   Groups (EAGS) 140–41  
*European Central Bank v DSS* (2008)  
   216  
 European Court of Justice (ECJ) 146,  
   147, 221  
 European Digital Rights Initiative  
   (EDRI) 118  
 European Patent Convention (EPC)  
   110, 132–3, 135, 136, 147, 218  
   diagnostic methods 225–6  
   medical treatment, methods of  
     223–4  
   specific, substantial and credible  
     standard (SSCS) 217  
 European Patent Litigation Agreement  
   221  
 European Patent Office (EPO) 132,  
   136, 146–7, 151, 154, 218  
   breast cancer genes 140  
   increasing returns 222–4, 225–6  
   incrementalism 228–9  
   inter-institutional linkages  
     217–19, 220, 221–2  
   quasi-judicial authority 215, 220  
   national courts 218  
   oncomouse 135, 220

- stem cells
  - human embryonic 145–6
  - process for identifying 145
- European Union 57, 166, 173, 218–19, 221, 233
- framing processes
  - biopatents *see* Biopatent Directive
  - IP enforcement *see* Enforcement Directive, IP
  - software *see* Software Patents Directive
- European Court of Justice (ECJ) 146, 147, 221
- Thailand 33, 34, 35, 45
- exporters: patents and Latin America 17
- Farrell, J. 230
- FFII (Foundation for a Free Information Infrastructure) 111, 116, 118, 123, 126
- films *see* digital movie industry *under* Germany
- finance ministries: patents and Latin America 17
- Finland 147
- Fischer, F. 130
- flea-markets 168
- FMC 200
- food industry 16
- foreign investors: patents and Latin America 16–17
- Fourtou, Janelly 117–18, 126
- framing processes 6, 40, 51, 56
  - conclusion 123–6
  - conflicts about EU directives 109–11
    - biopatents *see* Biopatent Directive
  - definition of frame 111
  - GMO frame 58
  - introduction 107–9
  - methodology: political claims analysis 111–12
  - patent offices 215
  - patent system: incrementalism 229
  - results 112–14
    - actors and actions 114–18
    - framing 118–23
- France 33, 35, 46–7, 48
  - Biopatent Directive 147, 150–51
  - patents 187
    - ownership of US and Australian 189, 190, 191, 195
  - political claims analysis 111, 112, 116, 117, 118
- free trade agreements (FTAs)
  - Thai–United States 30, 32, 35, 39–41, 50
- G8 summit (2007) 107, 108
- Gaisford, J.D. 81, 84, 87, 90
- Gamson, W.A. 108
- Gans, J.S. 226
- gene sequences *see* DNA sequences
- gene use restriction technology (GURT) 60, 75
- General Electric 200, 201
- General Motors 201
- genetically engineered (GE)
  - animals 228
    - oncomouse 135, 220
  - political framing of GMOs 56, 57, 58, 75
    - seeds *see* seeds, illicit
- Gerhards, J. 109
- Germany
  - digital movie industry 158–9
    - conclusion 174–7
    - hegemonic struggles: acceptance of IP law 167–70
    - materialist state theories 159–61
    - movie market 161–3, 178
    - movie production costs 178
    - non-licensed copying and re-regulation of IP law 163–7
    - public film funding law 158, 159, 162–3, 173–4, 175
    - relations of movie production and re-regulation of IP law 170–72
  - patents 193, 221
    - Biopatent Directive 145, 147, 148, 150–51
    - ownership of US and Australian 189, 190, 191, 195
    - winners, patent system 187
  - political claims analysis 111, 112, 116, 117, 118
- Geron 146

- Gillespie-White, L. 91  
 globalization and knowledge  
   paradigms 81–5  
 GMOs, political framing of 56, 57,  
   58, 75  
 Godt, C. 154, 155  
 Gold, A.G. 60  
 Gorlin, J. 108  
 Gottweis, H. 141  
 Gramsci, A. 158, 161, 167  
 grasses 75  
 Greaves, T. 88, 89  
 Greece 147  
 Greenpeace 138, 145  
 Greenwood, J. 108  
 Griffiths, W. 188  
 Griliches, Z. 187  
 Guellec, D. 153  
 Guennif, S. 42  
 Gupta, A.K. 59
- Haas, P.M. 221  
 Habermas, J. 130  
 Hall, B.H. 205, 228  
 Hall, P.A. 213  
 Hamilton, C. 82  
 Harhoff, D. 188  
 Hathaway, O. 229  
 Haunss, S. 5, 112, 118, 125  
 health: access to medicines 13, 20–21,  
   22, 25, 185  
   compulsory licences *see* compulsory  
   licences  
 Hein, W. 1, 109  
 Heinrich, S. 160  
 Heller, M.A. 148  
 Helpman, E. 3, 80  
 Henry, M.D. 220  
 Herring, R.J. 57, 58, 59, 60, 61, 63, 64,  
   65, 75  
 Hettinger, E.C. 3  
 Hewlett-Packard 201  
 Hilgartner, S. 60  
 Hitchcock, J. 221  
 HIV/AIDS 109  
   compulsory licences  
     Brazil 50  
     Thailand *see* Thailand: patents  
       and public health  
   treatments 38, 41–2, 51
- Hoechst 195  
 Hoodia plant 92, 98  
 Hope, J. 80  
 Hopkins, M. 146  
 Horrocks, S.M. 82, 88  
 human embryonic stem cells (hESCs)  
   145–7  
 human rights  
   medicines, access to 20, 21, 22  
   patent law 142–3, 152
- IBM 193, 200, 201  
 IFPI (International Federation of the  
   Phonographic Industry) 118, 120  
 IFPMA (International Federation of  
   Pharmaceutical Manufacturers  
   and Associations) 29, 33  
 illicit seeds *see* seeds, illicit  
 import tariffs: Thai exports to US 51  
 increasing returns, dynamics of 5–6  
   patents *see under* patents  
 India 35, 48, 84  
   Kani tribe 81, 87, 92–3, 101–2  
     benefit sharing agreement 93–100  
     identifying the Kanis 96–100, 101  
     key questions 85–6  
     lessons learnt 100  
   patents 90  
     based on indigenous knowledge  
       83, 92, 93, 96, 98  
     research in biotechnology 59, 61  
   transgenic crops 61  
     Bt cotton 56, 58, 59, 61–6, 68–73,  
       74, 75  
     IP rights: plant varieties and seeds  
       67–8  
     mustard 69  
 indigenous people 80–81, 101–2  
   definitions 91–2  
   globalization and knowledge  
     paradigms 81–5  
   Kani tribe 81, 87, 92–3, 101–2  
     benefit sharing agreement  
       93–100  
     identifying the Kanis 96–100,  
       101  
     key questions 85–6  
     lessons learnt 100  
   nation state and IPRs 86–91, 101  
   San tribe 92, 98, 101

- industry in Thailand, local 36–7  
 information technology sector 195  
 Intel 201  
 ‘intellectual property’, use of term 50  
 Internet  
   Act Up–Paris 46  
   Blackberry email service 231  
   movie industry 164, 165, 166, 167,  
     169, 170, 174, 175  
   transgenic seeds 74  
 Internet service providers 166  
 IPRED *see* Enforcement Directive, IP  
 Ireland 147  
 Israel 189–90  
 Italy 145, 146, 147, 151, 163  
  
 Jaffe, A.B. 183  
 Japan 16, 57, 131  
   patents 193  
     ownership of US and Australian  
       189, 190, 191, 194, 195, 201  
     patent office 218, 222  
 Jarothe, S. 163  
 Jayaraman, K.S. 59, 64  
 Jensen, A.K. 85  
 Jessop, B. 158, 160–61, 175  
 Johnson & Johnson 201, 207  
 Joshi, Sharad 63, 70  
  
 Kahin, B. 186  
 Kansa, E.C. 82, 84, 85, 86, 88, 89  
 Kapczynski, A. 14, 20  
 Karani, P. 80  
 Kazmin, A. 29  
 Kimberly-Clark 195  
 King, S.R. 91  
 Klingensmith, D. 89  
 Klug, H. 1  
 Knowledge Ecology International  
   (KEI) (formerly CPTEch) 36  
 Koesch, S. 168  
 Koopmans, R. 111, 112  
 Korea 193, 195, 201  
 Krasser, R. 150  
 Krefft, A.R. 133, 140  
 Krempl, S. 168  
 Krikorian, G.P. 39  
 Kuanpoth, J. 30  
 Kumar, N. 14  
 Kuttimathen Kani 81, 93, 94  
  
 Laird, S. 83  
 Lalitha, N. 67  
 Lambertson, D.M. 191  
 Landes, W.M. 183, 205, 215, 220, 227  
 Lanjouw, J.O. 229  
 Latin America  
   patents 13–15, 25–6  
     strengthening interests 16–19  
     weakening interests 19–25  
 lawyers  
   movie industry, German 166–7,  
     168  
   patents 131, 153, 186, 205  
     Latin America 17–18  
     Software Patents Directive 114,  
       115–16  
 Le Buanec, B. 67  
 Leith, P. 215, 223  
 Lemley, M. 3, 226  
 Lerner, J. 205  
 Levin, R.C. 184  
 light-manufacturing sector 17  
 Limpananont, J. 42  
 Lipton, M. 60  
 litigation, skewed nature of patent  
   229–32  
 Long, C. 227  
 Loypacher, L.J. 82  
*Lungren, Ex parte* (2005) 224  
 Luxembourg 147, 151  
 Lybbert, T.J. 61  
  
 Macdonald, S. 184, 185  
 Mahyco Monsanto Biotech Ltd  
   (MMBL) 62, 63, 64–5, 68–73, 75  
 maize, transgenic 58  
 Maltby, R. 162  
 Mandelson, Peter 33, 34, 35  
 Mansfield, E. 16, 184  
 market access 17  
 Martinez-Alier, J. 82  
 Marwell, G. 221  
 Marx, K. 159, 160, 170  
 Maskus, K.E. 1, 2, 81, 87  
 Matthews, D. 2, 5, 16  
 May, C. 1, 2, 14, 176  
 Mayntz, R. 130, 151  
 Mazzoleni, R. 184  
 Médecins Sans Frontières (MSF) 35,  
   36

- Meier, H.E. 108  
 'mental maps' 125, 214, 225  
 Merck 38, 46  
   Merck Sharp & Dohme Ltd 200  
 Merges, R.P. 3, 226  
*Merrell Dow Pharmaceuticals v HN Norton* (1996) 218  
 Mexico 58  
   patents 13–15, 25–6  
     strengthening interests 16–19  
     weakening interests 19, 20–25  
 Mgbeoji, I. 92  
 Micron Technologies 201  
 Microsoft 119, 126  
 military coup in Thailand 32, 44  
 Miller, H.I. 58, 59  
 Mohai, K.H. 80  
 Moir, H.V.J. 185, 191, 195, 200  
 Mongkol Na Songkhla 29, 43, 44, 47  
 Monsanto 57, 58, 59, 60, 61–2, 201  
 Moon, G. 80, 98  
 Morera, E. 161  
 Morocco 50  
 Morse 69  
 most-favored nation (MFN) access 17  
 movie industry, digital *see under* Germany  
 Müller, Florian 116  
 multinational companies *see* transnational corporations  
 Murray, F. 58  
 Murugkar, M. 72  
 mustard, GM 69  
 Musu, I. 87, 90  
 Myriad Genetics 140  
  
 Nack, R. 133  
 Naím, M. 61, 74  
 Nelson, R.R. 184  
 Netherlands 145, 146, 147  
 Newell, P. 82  
 Niebler, Angelika 117–18  
 Nit Phibunsongkhram 39  
 Nokia 116, 195  
 non-governmental organizations (NGOs) 20, 118, 138  
   indigenous people 84, 85, 98, 101–2  
   Thailand 35–6, 39–40, 42  
   transgenic crops 57, 59, 74  
  
 Nortel Networks 195  
 North, D.C. 213  
 Norway 146  
 Novartis 34  
*NTP, Inc v Research in Motion* (2005) 231  
 Nuss, S. 160  
  
 Offe, C. 160  
 Olson, M. 182  
 oncomouse, Harvard 135, 220  
 organic farmers 60  
 Oxfam 36  
  
 Paarlberg, R.L. 57, 74  
 Pakes, A. 187, 188  
 Pakistan 61  
 Paramount 163  
 Parthasarathy, S. 140  
 Patel, Piyush 64  
 patents  
   biopatents 222  
     animal varieties 211, 228  
     Directive *see* Biopatent Directive  
     oncomouse 135, 220  
     plants 67, 82–4, 87  
     plants: indigenous knowledge of India 83, 92, 93, 96, 98  
   empirical analysis: patent ownership introduction 182–5  
   losers, patent system 185–7  
   priorities for further research 204–6  
   US and Australia 189–92  
   US and Australia: corporate patenting 190–91, 192–204  
   winners, patent system 187–9  
 increasing returns 211–13  
   conclusion 232–3  
   doctrinal incoherence 216–17  
   incrementalism and uncertainty 227–9  
   inter-institutional linkages 217–22  
   litigation, skewed nature of 229–32  
   patent offices, role of 222–7  
   sources and features 213–17  
   sub-optimal outcomes 215–17  
   timing, value of 214–15  
 India 83, 90, 92, 93, 96, 98

- Latin America 13–15, 25–6  
 strengthening interests 16–19  
 weakening interests 19–25  
 software 6, 110, 186, 211, 219, 229  
 Directive *see* Software Patents Directive  
 Directive  
 specific, substantial and credible standard (SSCS) 217  
*see also* Enforcement Directive, IP path dependence 212, 214, 215, 227, 233  
 patients groups 20, 141  
 Pawar, Sharad 63  
 Penrose, E.T. 191  
 Pfizer 38, 80, 200  
 pharmaceutical patents 16, 184, 188  
 compulsory licences *see* compulsory licences  
 empirical analysis: Australian and US patent ownership 194, 195, 201  
 framing processes 109  
 India 90  
 Latin America 13, 15, 19–21, 22, 25  
 traditional knowledge 82, 89, 98  
 winners and losers, patent system 185, 188  
*see also* Biopatent Directive  
 Philippines 38  
 PhRMA (Pharmaceutical Research and Manufacturers of America) 33, 42, 47  
 Pierson, P. 212, 213–14, 215, 225, 229, 232  
 Pila, J. 229  
 plants  
 IP protection for plant varieties 67–8  
 traditional knowledge *see* traditional knowledge  
*see also* seeds, illicit  
 Poland: political claims analysis 111–12, 116, 117  
 political claims analysis *see* framing processes  
 Portugal 147  
 Potrykus, I. 57  
 Poulantzas, N. 158, 160  
 Pray, C. 70  
 prosumers 4  
 public goods 215, 230  
 Pugatch, M. 1  
 Pushpangadan, P. 81, 92  
 Ragavan, S. 84  
 Rai, A.K. 146  
 Ramachandran, R. 42  
 Ramanjaneyula, G.V. 60  
 Ramanna, A. 67  
 Ramaswami, D. 71  
 Reber, N. 177  
 regional and bilateral trade agreements (RBTAs) 2, 17  
 Rein, M. 130  
 Remiche, B. 29  
 Renesse, M. von 150  
 reverse-engineering 14  
 Rhodia 207  
 rice 75  
 Richardson, J. 108  
 Rocard, Michel 116  
 Roche 46  
 Rockwell International 200  
 Rojas, M.C. 86  
 Roy, D. 59, 69  
 Ryan, M.P. 2, 5, 182  
 Saengsuree Joota 34  
 Samak Sundaravej 48  
 San tribe 92, 98, 101  
 Sanguan Nittayarumpong 43  
 Sarnsamak, P. 34  
 Sarup, M. 82  
 Sayer, A. 160  
 Schankerman, M. 187  
 Scherer, F.M. 182, 184, 201, 205  
 Schmeiser, Percy 57  
 Schneider, I. 132, 133, 144, 146, 147, 150, 151, 154, 155  
 Schön, D. 131  
 Schröder, C. 162  
 Schweiger, T. 141  
 scientific community 18, 21–3, 47  
 Scotchmer, S. 3, 226  
 seeds, illicit 56  
 conclusions 73–5  
 counterfeit seeds 58, 59, 62, 65, 66, 74  
 stealth seeds distinguished from 56, 57



- development: bio-safety and bio-property 60–62
- introduction and overview 57–60
- IP: farmers' rights and breeders' rights 66–8
- transgenic cotton in India 56, 58, 59, 61–6, 74, 75
  - IP: farmers' rights and breeders' rights 67–8
  - stealth seeds, impact of 68–73
- Segrave, K. 176
- Sell, S.K. 1, 2, 5, 16, 30, 40, 107, 108, 182, 205
- Shadlen, K.C. 1, 2, 17, 21
- Shah, E. 71
- Shaji, K.A. 96, 98
- Sherman, B. 212
- Shiva, V. 61, 82, 84, 85, 89, 91
- Silverbrook Research 200
- Simeone, T. 84
- Sirilak Suteekul 34
- small and medium-sized enterprises (SMEs): framing processes
  - Biopatent Directive 134
  - Software Patents Directive 110, 114, 118, 121–2, 123, 124–5, 126
- Smith, S.E. 90
- SmithKline Beecham 141
- Snow, D.A. 40, 108, 109, 111, 122
- social movements 35, 50, 59
  - framing processes 108, 109
- Software Patents Directive 109–11, 132
  - conclusion 123, 124–6
  - methodology: political claims analysis 111–12
  - results 112, 113
    - actors and actions 114, 116–18
    - framing 118–19, 121–3
- somatic cell nuclear transfer (SCNT) 144
- South Africa: San tribe 92, 98, 101
- soy, transgenic 58
- Spain 147, 163
- Srinivasan, C.S. 68
- stem cells, human embryonic (hESCs) 145–7
- Stone, G.D. 59, 65
- Subramanian, A. 29
- Sumitomo Chemicals 195
- Svarstad, H. 60
- Switzerland 33, 195, 223
- Tanksley, S.D. 60
- technology transfer 100, 134
- Telecom Italia 116
- telecommunications sector 110, 195
  - ETNO (European Telecommunications Network Operators Association) 116–17, 118, 120
- terminator technology 60, 61, 75
- Thailand: illicit seeds 58, 61
- Thailand: patents and public health 29–31, 48–9
  - analyzing chosen events 37
    - Oct 2001: universal health cover 37–8
    - Jan 2006: mobilization 39–41
    - historical decision 41–3
    - Sept 2006: military coup 44
    - chain reaction 44–7
    - May 2007: diplomatic mission 47–8
  - players 32–7
- Thaksin Shinawatra 32, 37, 40, 44
- Thambisetty, S. 3, 215, 217, 218, 220, 224, 227, 229, 233
- Thiermeyer, M. 162
- Thomson, James 145
- Toffler, A. 4
- Tollison, R.D. 182, 186
- trade associations 16–17, 22, 33
  - see also individual associations*
- traditional knowledge 35, 80–81
  - bio-piracy 91–2
  - conclusion 101–2
  - definitions 91–2
  - globalization and knowledge paradigms 81–5
- Kanis: benefit sharing agreement 93–6, 101
  - identifying the Kanis 96–100
  - lessons learnt 100
- key questions 85–6
- nation state and IPRs 86–91, 101
- nature of 88
- transgenic seeds/crops *see* seeds, illicit
- transnational corporations (TNCs) 16, 222

- Biopatent Directive 134
- movie industry 161–2, 163, 164, 175–6
- seeds 58, 61
- Thailand and compulsory licences 29, 33–5
- TRIPS agreement 107–8
- see also individual corporations*
- Treerutkuarkul, A. 34
- Trilateral Offices 217, 218, 221–2
- TRIPS Agreement 2, 13, 17, 49, 224
  - compliance dates 19, 201
  - Doha Declaration 29–30, 34, 46, 47, 48
  - Germany 165
  - movie-related aspects 177
  - plant varieties 67
  - political process leading to 5, 16, 49, 107–8, 182, 183, 200–201, 207
  - traditional knowledge 87, 90
- tumeric 90–91
- Turkey 76
- Turner, J.L. 220
  
- Ullrich, H. 153
- UNDP 101
- Unilever 207
- United International Pictures 163
- United Kingdom 48, 147
  - patents 187, 211, 218, 219, 220–21, 223
  - computer programs 229
  - litigation 230–31, 233
  - ownership of US and Australian 189, 190, 191, 195
  - patent office (UKIPO) 219, 220–21, 222, 226–7
  - political claims analysis 111, 112, 116, 117, 118
- United Nations Development Programme 101
- United States 16, 40, 90, 108
  - Chambers of Commerce (AmChams) 16–17, 33, 46
  - movie industry 161–2, 163, 164, 173, 177, 178
  - patents 67, 90–91, 133, 140, 153, 193, 228
  - Biopatent Directive 134
  - Court of Appeals for the Federal Circuit (CAFC) 215, 219–20
  - human embryonic stem cells 145, 146
  - increasing returns: inter-institutional linkages 217–18, 219–20, 221–2
  - indigenous knowledge of India 83
  - litigation 231–2, 233
  - losers, patent system 185, 186
  - National Institutes of Health (NIH) 217–18, 233
  - ownership: empirical analysis 183, 189–93, 194–204, 205
  - patent office (USPTO) 222, 224–5, 226, 231, 232
  - ‘technological arts’ test 224
  - seeds 58, 60, 67, 76
  - Sony Bono Copyright Extension Act 1998 227
  - Thailand and compulsory licences 29, 33–4, 42, 45, 46, 50, 51–2
  - free trade agreement 30, 32, 35, 39–41
  - May 2007: diplomatic mission 47–8
  - Trade Representative (USTR) 33, 40, 41, 42, 45, 46, 47, 48, 52
  - UPOV (International Union for the Protection of New Varieties of Plants) convention 67
  - USA for Innovation 45, 46, 52
  - Van den Belt, H. 140
  - Van Overwalle, G. 144
  - Varma, A. 232
  - Velásquez, G. 29
  - Vichai Chokevivat 31
  - Vietnam 58, 61
  - Vrtovec, K.T. 146
  - Wagner, P.R. 219
  - Wagner, S. 205
  - Wall Street Journal* 45
  - Warner Bros 163
  - Warner Communications 207
  - Warshofsky, F. 201

- Wasko, J. 162  
Watal, J. 2  
Watson, D.S. 193  
Watson, James 140  
World Health Organization (WHO)  
38, 42, 51  
World Intellectual Property  
Organization (WIPO) 193, 218,  
222, 224  
copyright 108, 165, 166  
indigenous people 85, 101  
World Trade Organization (WTO) 13,  
17, 31, 205  
*see also* TRIPS Agreement  
Zilberman, D. 60  
Ziltener, P. 173  
Zylla, G. 168

